Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 19, 2025, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a global healthcare leader headquartered in Denmark, employing approximately 78,400 people across 80 countries and marketing products in around 170 countries.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase of ADRs |
| Insider | Christina Law (Member of the Board of Directors) |
| Total Volume | 2,350 ADRs |
| Total Value | DKK 820,252.49 |
| Transaction Date | August 18, 2025 |
| Exchange | New York Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely reports an initial notification of a purchase transaction by a board member.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a specific transaction.
Key Facts for Investor Verification
- Christina Law, a Member of the Board of Directors, purchased 2,350 Novo Nordisk ADRs on August 18, 2025.
- The total value of the transaction was DKK 820,252.49, executed at prices ranging from DKK 349.03 to DKK 349.06 per ADR.
- The transaction was executed on the New York Stock Exchange.
- This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or quarterly reports for financial metrics.